Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.70 |
| ▸ | RCE1 | Q9Y256 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21842239 | 0.86 | P4HB (0.74) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL21842238 | 0.86 | P4HB (0.74) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL21842498 | 0.84 | P4HB (0.66) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL11955293 | 0.83 | P4HB (1.00) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL21842473 | 0.83 | P4HB (0.81) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL13236178 | 0.83 | KDM4E (0.78) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL1816246 | 0.82 | RAB9A (0.82) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL21842484 | 0.82 | P4HB (0.67) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL14065375 | 0.82 | P4HB (0.63) | P4HBRCE1TP53CYP2C9CYP2C19 | |
| SCHEMBL21842241 | 0.81 | P4HB (0.66) | P4HBRCE1TP53CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061476-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | P4HB 2252/4885RCE1 360/4885TP53 6/4885 |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | P4HB 2832/4885RCE1 2434/4885TP53 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.